This page shows the latest Castleman's disease news and features for those working in and with pharma, biotech and healthcare.
drug. In J-ALEX - conducted by Roche's Japanese subsidiary Chugai - Alecensa reduced the risk of disease-worsening or death by 66% compared to Xalkori. ... First launched in Japan for 2005 for Castleman's disease - and subsequently getting the green
Roche wins early use RA approval for RoActemra in Europe. Adds to existing indications in arthritis and Castleman’ s disease. ... The study showed patients on the combination experienced a significantly greater improvement in disease activity (DAS28
EC approves Janssen rare blood disorder drug. Sylvant available to treat multicentric Castleman's disease. ... Janssen's Sylvant this week became the first drug approved in Europe to treat the rare blood disorder multicentric Castleman's disease (MCD).
FDA approves Janssen drug for rare Castleman’ s disease. Sylvant approved to treat lymphoma-like condition. ... It is also designated an orphan drug due to the rarity of multicentric Castleman's disease.
EMA backs Janssen rare disease drug for approval. Castleman's disease treatment Sylvant wins CHMP recommendation. ... J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe.
The stable of products that are nearing readiness to be filed with regulators in the US and EU includes bapineuzumab IV for Alzheimer's disease, which the company acquired from Elan ... Also on the list are fulranumab for osteoarthritis pain; siltuximab
More from news
Approximately 3 fully matching, plus 3 partially matching documents found.
No results were found
GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....